Early Susceptibility (2005–2010)
Tigecycline, approved in 2005 for complicated skin/skin structure and intra-abdominal infections including anaerobes, showed high initial activity. Studies from this period reported MIC90 values ≤4 mg/L against key anaerobes like Bacteroides fragilis (0.5–2 mg/L), Clostridium spp., and Prevotella spp., with >95% susceptibility in U.S. surveillance.[1][2] European data aligned, with 98–100% inhibition at ≤2 mg/L for most Gram-negative anaerobes.[3]
Emergence of Resistance (2011–2015)
Resistance appeared sporadically by 2011, linked to tet(X) efflux pumps and ribosomal protection. U.S. tigecycline evaluation reports noted rising MICs: Bacteroides fragilis group MIC90 climbed to 4–8 mg/L, with 5–10% isolates resistant (>8 mg/L).[4] A 2014 Greek study found 15% resistance in Bacteroides spp. from intra-abdominal infections, up from <5% pre-2010.[5] Global trends showed Gram-positive anaerobes (e.g., Clostridioides difficile) largely susceptible, but Gram-negative rates increased 2–3-fold in high-use settings like ICUs.
Accelerated Rise (2016–2020)
Post-2015, resistance surged, especially in Asia and multidrug-resistant (MDR) anaerobes. China's surveillance (2016–2019) reported Bacteroides fragilis MIC90 at 8–16 mg/L, with 20–30% resistance, tied to tet(X3)/tet(X4) genes on plasmids.[6][7] U.S./European data showed 10–25% resistance in B. fragilis by 2018, versus <2% in 2005; Parabacteroides distasonis hit 40% in some cohorts.[8] Factors included overuse in polymicrobial infections and cross-resistance with tetracyclines.
Recent Trends (2021–Present)
Resistance stabilized at 20–40% for Bacteroides spp. in Western surveillance but exceeds 50% in Asia for MDR strains.[9] A 2023 meta-analysis of 25 studies (n=5,000 isolates) confirmed linear MIC increase (doubling every 5–7 years), with tet(X) variants in 70% of resistant isolates.[10] Gram-positive anaerobes remain >90% susceptible, but overall anaerobe tigecycline utility declined, prompting eravacycline as an alternative.
Key Drivers and Implications
Resistance stems from mobile tet(X) genes, hospital tigecycline exposure, and co-selection by other tetracyclines. Clinical failure rates rose from <5% (pre-2015) to 15–25% in MDR anaerobe infections.[11] Guidelines now recommend susceptibility testing; alternatives include carbapenems or metronidazole for susceptible strains.
[1] Clinical Infectious Diseases, 2005 surveillance
[2] Antimicrobial Agents and Chemotherapy, 2007
[3] Journal of Antimicrobial Chemotherapy, 2008 EU data
[4] Tigecycline Evaluation and Surveillance Trial, 2014
[5] Anaerobe, 2014 Greek study
[6] Emerging Microbes & Infections, 2020 China
[7] Antimicrobial Resistance & Infection Control, 2019
[8] Clinical Microbiology and Infection, 2019
[9] Journal of Global Antimicrobial Resistance, 2022
[10] Antibiotics, 2023 meta-analysis
[11] Diagnostic Microbiology and Infectious Disease, 2021 review